E46.1 Million in Cash and Cash Equivalents as of September 30
Strasbourg, France, October 21, 2015 – Transgene S.A. (Euronext: TNG) today announced its quarterly financial results as of September 30, 2015 (third quarter of 2015).
During the third quarter of 2015, revenue from collaborative and licensing agreements was mainly related to research services and royalties.
Government financing for research expenditures mainly consisted of the research tax credit estimated for the first nine months of 2015 of E6.2 million.
Cash, cash equivalents, available-for-sale financial assets and other financial assets:
Cash, cash equivalents, available-for-sale financial assets and other financial assets amounted to E46.1 million as of September 30, 2015, compared to E65.9 million as of December 31, 2014.
Si le fichier PDF ne s'affiche pas ou pour le télécharger, cliquez ici.
Pour consulter le fichier PDF en intégralité, cliquez ici.
|TRANSGENE||Euronext Paris||3.33 (c)||-0.30%||24 860|